Sonorous Neurovascular secures FDA IDE approval to launch first U.S. pivotal trial of a venous sinus stent for pulsatile tinnitus
Executive summary: Sonorous Neurovascular received FDA IDE approval to initiate the first U.S. pivotal trial of its venous sinus stent for pulsatile tinnitus, adding a U.S. arm to the international B-SILENT 2 study. This is the first U.S. pivotal trial for a device targeting pulsatile tinnitus, potentially opening a new treatment avenue and regulatory pathway for venous sinus stenting.
Who is involved: Sonorous Neurovascular (clinical‑stage medical device company), the FDA (granting the IDE), investigators and patients with pulsatile tinnitus.
Likely next (inference): Activation of U.S. trial sites, patient enrollment in the coming months, collection of safety and efficacy data leading to a potential PMA submission upon success.
On October 7, 2026, Sonorous Neurovascular announced that the U.S. Food and Drug Administration granted an Investigational Device Exemption (IDE) for its venous sinus stent, enabling the first U.S. pivotal study of the device to treat pulsatile tinnitus. The approval adds a U.S. arm to the company's ongoing B-SILENT 2 international clinical program. This step clears a regulatory pathway for potential future premarket approval if the trial meets safety and efficacy endpoints. No financial terms or trial site details were disclosed in the release.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base: Trial proceeds as planned (50%)
Enrollment begins in coming months; data readout expected within 12‑18 months, supporting a potential PMA filing.
- First site activation and patient enrollment expected within the next 3‑6 months
- Interim safety review scheduled after first 20 patients
- Primary efficacy results anticipated 12‑18 months after first enrollment
Upside: Positive early outcomes accelerate approval (30%)
Strong efficacy and safety signals could lead to an early feasibility study or expedited PMA submission, shortening time to market.
- Primary endpoint met with statistical significance at interim analysis
- FDA grants breakthrough device designation based on trial data
- Manufacturing scale‑up initiated ahead of final data
Downside: Enrollment or safety issues delay program (20%)
Slow patient recruitment or adverse events would push the timeline back, increasing development costs and potentially requiring trial redesign.
- Enrollment rate below 5 patients per month after three months
- FDA requests additional preclinical safety data
- Serious adverse event triggers a clinical hold
What to watch
- FDA updates on IDE status or any additional requests within the next 6‑8 weeks
- Announcement of first clinical site activation or patient enrollment within the next 2‑3 months
- Release of interim safety data after the first 20‑30 patients, expected within 6‑9 months of first enrollment
- Any press release or SEC filing indicating financing or partnership developments related to the trial within the next quarter
Timeline
- — Sonorous Neurovascular Receives FDA IDE Approval for First U.S. Pivotal Trial of a Venous Sinus Stent to Treat Pulsatile Tinnitus (PR Newswire)
Analysis — what this means
Likely next events
- First U.S. site activation expected within the next 3‑6 months
- Initial patient enrollment anticipated within 4‑7 months
- Interim safety review after first 20 patients expected within 6‑9 months
- Primary efficacy data readout projected 12‑18 months after first enrollment
Sectors affected
- venous sinus stent market
- pulsatile tinnitus treatment
- neurovascular interventional devices
Regulatory implications
- FDA IDE permits initiation of a U.S. pivotal study for the venous sinus stent
- Positive trial outcomes could support a future Premarket Approval (PMA) application
- The IDE triggers standard FDA post‑approval reporting requirements and monitoring
Historical parallels
- FDA IDE approval for the Wingspan intracranial stent (2005) – first IDE for a neurovascular stent
- FDA IDE approval for the Pipeline embolization device (2009) – prior neurovascular device pathway
Key entities
Sources
Related cases
- FDA’s expanded allowance for non‑animal safety testing enables VivoSim’s human‑relevant models to cut drug‑development costs
- CraniUS Therapeutics secures rapid FDA 510(k) clearance and a U.S. patent for its NeuroPASS cranial drug‑delivery system
- Dr. Oregonin secures FDA registration for OLTIS DENTAL‑X, launching a botanical oral‑care product grounded in a 1974 OSU discovery and two decades of South Korean research
- Roche’s BTK inhibitor fenebrutinib gains FDA filing acceptance for both relapsing and primary progressive MS, marking a potential first-in-class oral therapy
- Food safety attorney pushes FDA for mandatory warning labels on raw sprouts following multi-state outbreak
- XtalPi files first IND for AI-discovered gut-restricted pan-TRK inhibitor, marking clinical-stage transition